Thera-SAbDab

EPCORITAMAB

>   Structural Summary
TherapeuticEpcoritamab
Target 1CD3E
Heavy Chain 1EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS
Light Chain 1QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2MS4A1
Heavy Chain 2EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS
Light Chain 2EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 Structure3giz [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Epcoritamab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.25%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102 103 104 105 106 107 108 109 110 111 112 113
epcoritamab_Fv2 E V Q L V E S G G G L V Q P D R S L R L S C A A S G F T F H D Y A M H W V R Q A P G K G L E W V S T I S W N S G T I G Y A D S V K G R F T I S R D N A K N S L Y L Q M N S L R A E D T A L Y Y C A K D I Q Y G N Y Y Y G M D V W G Q G T T V T V S S
3giz E V Q L V E S G G G L V Q P G R S L R L S C A A S G F T F N D Y A M H W V R Q A P G K G L E W V S T I S W N S G S I G Y A D S V K G R F T I S R D N A K K S L Y L Q M N S L R A E D T A L Y Y C A K D I Q Y G N Y Y Y G M D V W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
epcoritamab_Fv2 E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P I T F G Q G T R L E I K
3giz E I V L T Q S P A T L S L S P G E R A T L S C R A S Q S V S S Y L A W Y Q Q K P G Q A P R L L I Y D A S N R A T G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S N W P I T F G Q G T R L E I K
>   Metadata
FormatBispecific mAb
IsotypeG1
Highest Clinical Trial (Jan '20)Phase-I/II
Estimated Status (Jan '20)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedGenmab
Conditions Approvedna
Conditions ActiveHaematological malignancies
Conditions Discontinuedna
NotesSecond Fv closely related to Ofatumumab

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]